Screening of Rubella Virus, Cytomegalovirus, Hepatitis B Virus, Hepatitis C Virus, HIV, Syphilis, and Toxoplasma gondii Antibodies in Pregnant Women

TORCH pathogens are often asymptomatic in healthy adults but can cause foetal death when transmitted during pregnancy; therefore, accurate regional data are essential for screening. This study aimed to determine first-trimester TORCH seropositivity and to inform the development of hospital-based and national screening algorithms. This study analysed test results from 7481 pregnant women aged 15-49 years who participated between January 2020 and December 2024. TORCH serological results obtained using the MAGLUMI X3/X6 system (Snibe, Shenzhen, China) were analysed with Statistical Package for the Social Sciences. Anti-HCV positivity was 0.12% (9/7166), anti-<i>Toxoplasma gondii</i> IgG positivity was 16.5% (1027/6204), anti-rubella IgG positivity was 95.5% (5809/6080), and anti-CMV IgG positivity was 98.69% (6130/6211). Syphilis seropositivity among pregnant women was 0.2% (13/4991). Significant differences by age groups (15-24, 25-34, and >35 years) were observed for rubella IgG (<i>p</i> < 0.001), <i>T. gondii</i> IgG (<i>p</i> < 0.001), and HBsAg positivity (<i>p</i> = 0.009). This study investigated TORCH seropositivity among pregnant women in our hospital region and underscores the need for targeted public health initiatives to reduce the risk of congenital infections. It recommends systematic first-trimester assessment of TORCH exposure, standardized data recordings, the establishment of national screening programmes, and careful consideration of testing costs.